Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient

Wiener Klinische Wochenschrift

Volumn 108, Issue 14, 1996, Pages 425-431

  Jansen, M ^a   Gabriel, H ^a   Banyai, S ^a   Pidlich, J ^a   Weidinger, F ^a   Horl W H ^a   Derfler, K ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

coronary heart disease; cyclosporine A; hyperlipidemia; immunosuppression; LDL apheresis; LDL immunoadsorption; Lp(a); renal transplantation

Indexed keywords

ADULT; ANGINA PECTORIS; APHERESIS; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; IMMUNOADSORPTION; ISCHEMIC HEART DISEASE; KIDNEY GRAFT; MALE; TREATMENT OUTCOME;

ADULT; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FOLLOW-UP STUDIES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOSORBENT TECHNIQUES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEINS, LDL; MALE; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 0029901868     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493
2. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM, Young JB (1989) Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53-56
3. Biesenbach G, Janko O, Stuby U, Zazgornik J (1996) Terminales myoglobinurisches Nierenversagen unter Lovastatintherapie bei präexistenter chronischer Nierenfunktionsstörung. Wien Klin Wochenschr 108: 334-337
4. Blankenhorn DH, Azen SP, Kramsch DM (1993) Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119: 969-976
5. Brown G, Albers JJ, Fisher LD (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298
6. Chan MK, Varghese Z, Persaud JW, Fernando ON, Moorhead JF (1981) The role of multiple pharmaco-therapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol 15: 309-313
7. Chan TM, Cheng KP, Tam CF (1994) Hyperlipidemia after renal transplantation: treatment with gemfibrozil. Nephron 67: 317-321
8. Corpier CL, Jones PH, Suki WN, Ledererf ED, Quinones MA, Schmidt SW, Young JB (1988) Rhabdomyolysis and renal injury with lovastatin use. JAMA 260: 239-241
9. DeGroen P (1988) Cyclosporin, low-density lipoprotein, and cholesterol. Mayo Clin Proc 63: 1012
10. Derfler K, Kletter K, Heinz G, Dudczak R (1991) Predictive value of Thallium 201-DPM stress scintigraphy in chronic HD patients and RTFs. Clin Nephrol 36: 192-202
11. Derfler K, Hayde M, Heinz G, Hirschl MM, Steger G, Hauser AC, Balcke P, Widhalm K (1991) Decreased post-heparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int 40: 720-727
12. Divakar D, Bailey RR, Frampton CM, Geotge PM, Walmsley TA, Murphy J (1991) Hyperlipidemia in stable renal transplant recipients. Nephron 59: 423-428
13. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318: 47-48
14. Fassbinder W, Challah S, Brynger E (EDTA Registry) (1987) Long-term results of renal transplantation in Europe. Transplant Proc 19: 3754-3760
15. Gruber C, Svoboda K, Pidlich J, Gottsauner-Wolf M, Sunder-Plassmann G, Pamberger P, Jansen M, Derfler K, Widhalm K (1993) Reduction of Lipoprotein(a) by immunospecific LDL-apheresis. In: Gotto AM Jr, Mancicni M, Richter WO, Schwandt P (eds) Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease. Karger, Basel, pp 219-222
16. Harris KPJ, Russell GI, Parvin SD, Veitch PS, Walls J (1986) Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J 292: 16
17. Hricik DE (1994) Posttransplant hyperlipidemia: the treatment dilemma. Am J Kidney Dis 23: 766-771
18. Jackson JM, Lee HA (1982) The role of propanolol therapy and proteinuria in the etiology of post renal transplantation hyperlipidemia. Clin Nephrol 18: 95-100
19. Kasiske BL, Ulmen AJ (1987) Persistent hyperlipidemia in renal transplant patients. Medicine 66: 309
20. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF (1988) Treatment of hyperlipidemia reduces glomerular injury in the obese Zucker rat. Kidney Int 33: 667-672
21. Kasiske BL (1988) Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84: 985-992
22. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV (1991) The adverse impact of cyclosporin on serum lipids in renal transplant recipients. Am J Kidney Dis 27: 700-707
23. Kasiske BL (1993) Risk factors for cardiovascular disease after renal transplantation. Miner Electrolyte Metab 19: 186-195
24. Keane WF, Kasiske BL, O'Donnell MP (1988) Hyperlipidemia and progression of renal disease. Am J Clin Nutr 47: 157-160
25. Keane WF, Kasiske BL, O'Donnell MP, Kim J (1991) The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 17: 38-42
26. Keane WF (1996) Lipids and progressive renal failure. Wien Klin Wochenschr 108: 420-424
27. Kritz H, Sinzinger H (1995) Atherosclerotic lesions in humans - plaque stabilization and regression. Wien Klin Wochenschr 107: 555-566
28. MAAS Investigators (1994) Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS). Lancet 344: 633-638. [Erratum. Lancet (1994) 344: 762]
29. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF (1993) Low-dose simvastatin is safe in hyperlipidemic renal transplant patients. Nephrol Dial Transplant 8: 637-641
30. Moore RA, Callahan MF, Cody M, Adams PL, Litchford M, Buckner K, Galloway J (1990) The effect of the American heart association step one diet on hyperlipidemia following renal transplantation. Transplantation 49: 60-62
31. Norman DJ, Illingworth DR, Munson J, Hosenpud J (1988) Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin. N Engl J Med 318: 46-47
32. Raine AEG, Carter R, Mann JI, Morris PJ (1988) Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 3: 458-463
33. Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P (1993) Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42: 888-894
34. Rubba P, Mancini M (1995) Lipid-lowering treatment: effects on endothelial dysfunction. Current Opinion Lipidology 6: 348-353
35. Svoboda K, Derfler K, Koppensteiner R, Langer M, Pamberger P, Brehm R, Ehringer H, Druml W, Widhalm K (1993) Extracorporeal lipid elimination for treatment of gestational hyperlipidemic pancreatitis. Gastroenterology 104: 1527-1531
36. Taskinen M-R, Nikkila EA, Pelkonen R, Sane T (1983) Plasma lipoproteins, lypolytic enzymes, and very-low-density-lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 57: 619-628
37. Traindl O, Reading S, Franz M, Watschinger B, Klauser R, Pidlich H, Widhalm K, Pohanka E, Kovarik J (1992) Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect of LDL-cholesterol and lipoprotein(a). Nephron 62: 394-398
38. Treasure CB, Klein JL, Weintraub WS, Talley D, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi S, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487
39. Vanhaecke J, Cleemput JV, Lierde JV, Daenen W, DeGeest H (1994) Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 58: 42-45
40. Vathsala A, Weinberg RB, Schoenberg L, Grevels J, Goldstein RA, Van Buren CT, Lewis RM, Kahan BD (1989) Lipid abnormalities in cyclosporin-prednisone-treated renal transplant recipients. Transplantation 48: 37-43
41. Wanner C, Frommherz K, Hörl WH (1991) Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects. Cardiology 78: 202-217
42. Wenke K, Thiery J, Arndt N, Meiser BM, Seidel D, Reichart B (1992) Treatment of hypercholesterolemia and prevention of coronary artery disease after heart transplantation by combination of low-dose simvastatin and HELP-LDL-apheresis. Transplant Proc 24: 2674-2676
43. Würzner R, Schuff-Werner P, Franzke A, Nitze R, Oppermann M, Armstrong VW, Eisenhauer T, Seidl D, Götze O (1991) Complement activation and depletion during LDL-apheresis by heparin-induced extracorporeal LDL-precipitation (HELP). Europ J Clin Invest 21: 288-294
44. Yokoyama S, Hayashi R, Satini M, Yamamoto A (1985) Selective removal of low-density lipoproteins by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 5: 613-621
45. Yoshimura N, Oka T, Okamoto M, Ohmori Y (1992) The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 53: 94-90